Adaptive Biotechnologies Corp (ADPT)

NASD · Healthcare · Diagnostics & Research · USA

Adaptive Biotechnologies Corp is a mid cap company (market value between $2 billion and $10 billion) in the Diagnostics & Research industry.

Adaptive Biotechnologies uses proprietary sequencing technology to decode patients' adaptive immune systems for disease diagnosis and treatment. Its MRD business offers clonoSEQ, an FDA-authorized test measuring minimal residual disease in lymphoid cancers, to clinicians and biopharmaceutical companies. The Immune Medicine business provides immune receptor sequencing and target discovery based on proprietary datasets of immune signatures and receptor-antigen matches.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Adaptive Biotechnologies Corp stock.

Our verdict on ADPT

Overvalued: intrinsic value $4.67 per share, market price $28.49, margin of safety -509.9% (as of 2026-11-17).

A 2.7x revenue multiple, discounted for its losses, values the shares at $4.67; the price of $28.49 is 510% above that value.

ETFs with the most weight in ADPT

17 more funds hold it; the full list is part of the paid plan.

More on ADPT

Browse

Peers in Diagnostics & Research

All 44 Diagnostics & Research stocks

Cheaper than ADPT in Diagnostics & Research

19 more in this industry show a wider margin of safety.

Is ADPT undervalued or overvalued?

ADPT is overvalued (as of the 2026-11-17 close). A 2.7x revenue multiple, discounted for its losses, values the shares at $4.67; the price of $28.49 is 510% above that value.

What is the intrinsic value of ADPT?

$4.67 per share (as of the 2026-11-17 close), against a market price of $28.49. That is a margin of safety of -509.9%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.